Table 1.
Main characteristics of the analyzed studies containing CBX-loaded nanocarriers in the context of cancer regarding trial approaches, targeted tumor type, proposed administration of the nanocarrier and specific therapeutic target
| Citation | Publication date | Trial approach | Type of targeted tumor | Proposed administration | Specific therapeutic target |
|---|---|---|---|---|---|
| Kim et al. [40] | 2011 | In vitro | Glioma | Intravenous | Tumor cells |
| Venkatesan et al. [41] | 2011 | In vitro | Colorectal | Intravenous | Tumor cells |
| Bragagni et al. [42] | 2012 | In vitro | Skin | Transdermal | Tumor cells |
| Kang et al. [43] | 2012 | In vitro | N.S. | N.S. | Tumor cells |
| O’Hanlon et al. [44] | 2012 | In vitro | N.S. | Parenteral | Microenvironment* |
| Erdoğ et al. [45] | 2013 | In vitro | Colorectal | Intravenous | Tumor cells |
| Patel, A. R. et al. [46] | 2013 | In vivo | Lung | Inhalation | Tumor cells |
| Patel, S.K, et al. [47] | 2013 | In vitro | N.S. | Intravenous | Microenvironment |
| Emami et al. [48] | 2014 | In vitro | Lung | Inhalation | Tumor cells |
| Ju et al. [49] | 2014 | In vivo | Breast | Intravenous | Vasculogenesis** |
| Vera et al. [50] | 2014 | In vitro | Glioblastoma | Intravenous | Tumor cells |
| Limasale et al. [51] | 2015 | In vitro | N.S. | Intravenous | Tumor cells |
| Said-Elbahr et al. [52] | 2016 | In vivo | Lung | Inhalation | Tumor cells |
| Yen et al. [53] | 2016 | Pre-formulation | Oral carcinoma | Epidermal | Susceptible non-tumoral cells† |
| Elzoghby et al.a [31] | 2017 | In vivo | Breast | Intravenous | Tumor cells |
| Elzoghby et al.,b [35] | 2017 | In vivo | Breast | Intravenous | Tumor cells |
| Gowda et al. [54] | 2017 | In vivo | Melanoma | Intravenous | Tumor cells |
| Riahi et al. [55] | 2017 | In vivo | N.S. | Intravenous | Tumor cells |
| Wu et al. [56] | 2017 | In vitro | N.S. | N.S. | Tumor cells |
| AbdElhamid et al.a [57] | 2018 | In vivo | Breast | Parenteral, N.S. | Tumor cells |
| AbdElhamid et al.b [58] | 2018 | In vivo | Breast | Intravenous | Tumor cells |
| Abdelmoneen et al. [59] | 2018 | In vivo | Hepatocellular carcinoma | Oral | Tumor cells |
| Hong et al. [60] | 2018 | Pre-formulation | N.S. | Intravenous | Tumor cells |
| Shi et al. [61] | 2018 | In vivo | N.S. | Intravenous | Tumor cells |
| Singh [62] | 2018 | In vitro | Skin | N.S. | Tumor cells |
| Uram et al. [63] | 2018 | In vitro | Glioblastoma multiforme | Topical, N.S. | Tumor cells |
| Yu et al. [64] | 2018 | In vitro | Breast | N.S. | Tumor cells |
| Ahmed et al. [65] | 2019 | In vivo | Melanoma | Epidermal | Tumor cells |
| Huang et al. [66] | 2019 | In vivo | N.S. | Intravenous | Microenvironment and tumor cells |
| Liu et al. [67] | 2019 | In vivo | N.S. | Parenteral, N.S. | Tumor cells |
| Sun et al. [68] | 2019 | In vivo | Breast | Intravenous | Microenvironment |
| Tian et al. [69] | 2019 | In vitro | Prostate | N.S. | Tumor cells |
| Üner et al. [70] | 2019 | In vitro | N.S. | N.S. | Tumor cells |
| Zhang et al. [71] | 2019 | In vivo | Breast | Intravenous | Tumor cells |
| Uram et al. [72] | 2019 | In vitro | Glioblastoma multiforme | Topical | Tumor cells |
| Zhang et al. [73] | 2019 | In vivo | Breast | Intravenous | Microenvironment and tumor cells |
| Liu et al. [74] | 2020 | In vivo | Breast | Parenteral, subcutaneous | Microenvironment and tumor cells |
| Xu et al. [75] | 2020 | In vivo | Melanoma | Intravenous | Microenvironment |
| Xv et al. [76] | 2020 | In vivo | Melanoma | Parenteral, subcutaneous | Tumor cells |
| Sun et al. [77] | 2020 | In vivo | Breast | Intravenous | Tumor cells |
| Lee et al. [78] | 2020 | In vivo | Non-small lung cancer | Intravenous | Microenvironment and tumor cells |
| Uram et al. [79] | 2020 | In vivo | Glioblastoma multiforme | Intravenous | Tumor cells |
| Ahmed et al. [80] | 2021 | In vitro | Breast | Intravenous | Tumor cells |
| Farooq et al. [81] | 2021 | In vitro | N.S. | N.S. | Tumor cells |
| Yan et al. [82] | 2021 | In vivo | N.S. | Intravenous | Microenvironment and tumor cells |
| Said-Elbahr et al. [83] | 2022 | In vivo | Lung | Inhalation | Tumor cells |
| Guo et al. [84] | 2022 | In vivo | Breast | Parenteral, subcutaneous | Microenvironment and tumor cells |
| Alajani et al. [85] | 2022 | In vitro | N.S. | Oral | Tumor cells |
| Wróbel et al. [86] | 2022 | In vitro | Glioblastoma | N.S. | Tumor cells |
| Mabrouk et al. [87] | 2023 | In vivo | Oral carcinoma | Topical | Microenvironment and tumor cells |
| Jahani et al. [88] | 2023 | In vivo | Melanoma | Intravenous | Microenvironment and tumor cells |
| Cao et al. [89] | 2023 | In vivo | N.S. | Intravenous | Microenvironment and tumor cells |
| Abdellatif et al. [90] | 2023 | In vitro | Skin | Topical | Tumor cells |
| Basheer et al. [91] | 2023 | In vitro | Breast | N.S. | Tumor cells |
| Mendes et al. [92] | 2023 | In vitro | Glioblastoma | Parenteral | Tumor cells |
| Kaur et al. [93] | 2023 | In vitro | Bone metastasis | N.S. | Tumor cells |
| Liu et al. [94] | 2024 | In vivo | Melanoma | Intravenous | Microenvironment and tumor cells |
| Cai et al. [95] | 2024 | In vivo | N.S. | Intravenous | Microenvironment and tumor cells |
*Tumor surroundings intensely modulated by tumor cells and/or the immune system
**De fato blood vessels or mimics induced by the tumor
†Cells of patients who are in risk groups for determinate cancer type. N.S. stands for “not specified”